Altamira Therapeutics Ltd. (CYTO)
NASDAQ: CYTO · Real-Time Price · USD
0.425
-0.015 (-3.39%)
Nov 21, 2024, 11:01 AM EST - Market open
Altamira Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
1.45M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SCWorx | 3.22M |
China SXT Pharmaceuticals | 1.93M |
TFF Pharmaceuticals | 1.20M |
Tivic Health Systems | 957.00K |
Helius Medical Technologies | 502.00K |
CYTO News
- 6 weeks ago - Altamira Therapeutics Provides Update on Nasdaq Listing - GlobeNewsWire
- 7 weeks ago - Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray - GlobeNewsWire
- 2 months ago - Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - GlobeNewsWire
- 2 months ago - Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - GlobeNewsWire
- 2 months ago - Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 - GlobeNewsWire